Insight

Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer

Emmy Boerrigter/LinkedIn

Dec 30, 2024, 13:30

Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer

A recent paper by Emmy Boerrigter, Pharmacist at Radboudumc Research Institute for Medical Innovation, was mentioned by European Urology Oncology on X:

“A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with PCa by Emmy Boerrigter, Joanneke K. Overbeek et al.”

“A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer”

Authors: Emmy Boerrigter, Joanneke Overbeek, Guillemette Benoist, Inge van Oort, Nielka van Erp et al.

More posts featuring European Urology Oncology.

cancer Emmy Boerrigter European Urology Oncology Guillemette Benoist Inge van Oort Joanneke Overbeek Nielka van Erp OncoDaily Oncology prostate cancer

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25